Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDL BioPharma Product Sales Up 25 Percent On Cardene Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm is focused on lifecycle management for Cardene as well as partnering opportunities for investigational drugs ularitide and Nuvion, CEO says.

You may also be interested in...



PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan

In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.

PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan

In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.

PDL BioPharma Plans To Divest Assets, Emerge As Pure Play Biotech

Sale of PDL’s lucrative royalty stream or even the company itself is not off the table as reorganization unfolds.

Related Content

Topics

UsernamePublicRestriction

Register

PS066531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel